| Grouping | The leading mutation | MPR | pCR | Mean residual tumor cells (%) | ||||||
| Driver mutations | EGFR N = 13 | 3/13 (23%) | 0/13 (0%) | 43.4% (SD35) | ||||||
| BRAF N = 1 | 0/1 (0%) | 0/1 (0%) | 45% | |||||||
| RET N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| ROS N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| No driver mutations | FGFR N = 2 | 2/2 (100%) | 2/2 (100%) | 0% (SD 0) | ||||||
| KRAS N = 10 | 8/10 (80%) | 4/10 (40%) | 13.7% (SD 23) | |||||||
| ERBB4 N = 1 | 1/1 (100%) | 0/1 (100%) | 5% | |||||||
| AKT amplification N = 1 | 1/1 (100%) | 0/1 (100%) | 9% | |||||||
| Negative for mutation N = 17 | 11/17 (64.7%) | 3/17 (17.6%) | 19.9% (SD24) | |||||||
| Biomarker grouping | MPR (n, %) | p-value | pCR (n, %) | p-value | MRTC (%, SD) | p-value | ||||
| Driver mutations N = 16 | 3/16 (19%) | 0.0001 | 0/16 (0%) | 0.004 | 44.4% (SD 31) | 0.001 | ||||
| EGFR only mutations N = 13 | 3/13 (23%) | 0.003 | 0/13 (0%) | 0.02 | 43.4% (SD 35) | 0.009 | ||||
| No driver mutations N = 31 | 22/31 (71%) | reference | 8/31 (26%) | reference | 15.8% (SD 22.4) | reference | ||||
| Grouping | The leading mutation | MPR | pCR | Mean residual tumor cells (%) | ||||||
| Driver mutations | EGFR N = 13 | 3/13 (23%) | 0/13 (0%) | 43.4% (SD35) | ||||||
| BRAF N = 1 | 0/1 (0%) | 0/1 (0%) | 45% | |||||||
| RET N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| ROS N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| No driver mutations | FGFR N = 2 | 2/2 (100%) | 2/2 (100%) | 0% (SD 0) | ||||||
| KRAS N = 10 | 8/10 (80%) | 4/10 (40%) | 13.7% (SD 23) | |||||||
| ERBB4 N = 1 | 1/1 (100%) | 0/1 (100%) | 5% | |||||||
| AKT amplification N = 1 | 1/1 (100%) | 0/1 (100%) | 9% | |||||||
| Negative for mutation N = 17 | 11/17 (64.7%) | 3/17 (17.6%) | 19.9% (SD24) | |||||||
| Biomarker grouping | MPR (n, %) | p-value | pCR (n, %) | p-value | MRTC (%, SD) | p-value | ||||
| Driver mutations N = 16 | 3/16 (19%) | 0.0001 | 0/16 (0%) | 0.004 | 44.4% (SD 31) | 0.001 | ||||
| EGFR only mutations N = 13 | 3/13 (23%) | 0.003 | 0/13 (0%) | 0.02 | 43.4% (SD 35) | 0.009 | ||||
| No driver mutations N = 31 | 22/31 (71%) | reference | 8/31 (26%) | reference | 15.8% (SD 22.4) | reference | ||||
Abbreviations: Epidermal growth factor receptor (EGFR), Major pathologic response (MPR), Mean residual tumor cells (MRTC) Pathologic complete response (pCR). The driver mutations group include EGFR, RET, ROS1 and BRAF. The EGFR only group excluded RET, ROS and BRAF from the analysis. P values are for comparison of no- driver mutations to driver mutations and EGFR only mutations.
| Grouping | The leading mutation | MPR | pCR | Mean residual tumor cells (%) | ||||||
| Driver mutations | EGFR N = 13 | 3/13 (23%) | 0/13 (0%) | 43.4% (SD35) | ||||||
| BRAF N = 1 | 0/1 (0%) | 0/1 (0%) | 45% | |||||||
| RET N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| ROS N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| No driver mutations | FGFR N = 2 | 2/2 (100%) | 2/2 (100%) | 0% (SD 0) | ||||||
| KRAS N = 10 | 8/10 (80%) | 4/10 (40%) | 13.7% (SD 23) | |||||||
| ERBB4 N = 1 | 1/1 (100%) | 0/1 (100%) | 5% | |||||||
| AKT amplification N = 1 | 1/1 (100%) | 0/1 (100%) | 9% | |||||||
| Negative for mutation N = 17 | 11/17 (64.7%) | 3/17 (17.6%) | 19.9% (SD24) | |||||||
| Biomarker grouping | MPR (n, %) | p-value | pCR (n, %) | p-value | MRTC (%, SD) | p-value | ||||
| Driver mutations N = 16 | 3/16 (19%) | 0.0001 | 0/16 (0%) | 0.004 | 44.4% (SD 31) | 0.001 | ||||
| EGFR only mutations N = 13 | 3/13 (23%) | 0.003 | 0/13 (0%) | 0.02 | 43.4% (SD 35) | 0.009 | ||||
| No driver mutations N = 31 | 22/31 (71%) | reference | 8/31 (26%) | reference | 15.8% (SD 22.4) | reference | ||||
| Grouping | The leading mutation | MPR | pCR | Mean residual tumor cells (%) | ||||||
| Driver mutations | EGFR N = 13 | 3/13 (23%) | 0/13 (0%) | 43.4% (SD35) | ||||||
| BRAF N = 1 | 0/1 (0%) | 0/1 (0%) | 45% | |||||||
| RET N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| ROS N = 1 | 0/1 (0%) | 0/1 (0%) | 50% | |||||||
| No driver mutations | FGFR N = 2 | 2/2 (100%) | 2/2 (100%) | 0% (SD 0) | ||||||
| KRAS N = 10 | 8/10 (80%) | 4/10 (40%) | 13.7% (SD 23) | |||||||
| ERBB4 N = 1 | 1/1 (100%) | 0/1 (100%) | 5% | |||||||
| AKT amplification N = 1 | 1/1 (100%) | 0/1 (100%) | 9% | |||||||
| Negative for mutation N = 17 | 11/17 (64.7%) | 3/17 (17.6%) | 19.9% (SD24) | |||||||
| Biomarker grouping | MPR (n, %) | p-value | pCR (n, %) | p-value | MRTC (%, SD) | p-value | ||||
| Driver mutations N = 16 | 3/16 (19%) | 0.0001 | 0/16 (0%) | 0.004 | 44.4% (SD 31) | 0.001 | ||||
| EGFR only mutations N = 13 | 3/13 (23%) | 0.003 | 0/13 (0%) | 0.02 | 43.4% (SD 35) | 0.009 | ||||
| No driver mutations N = 31 | 22/31 (71%) | reference | 8/31 (26%) | reference | 15.8% (SD 22.4) | reference | ||||
Abbreviations: Epidermal growth factor receptor (EGFR), Major pathologic response (MPR), Mean residual tumor cells (MRTC) Pathologic complete response (pCR). The driver mutations group include EGFR, RET, ROS1 and BRAF. The EGFR only group excluded RET, ROS and BRAF from the analysis. P values are for comparison of no- driver mutations to driver mutations and EGFR only mutations.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
